Explore the words cloud of the ImmUniverse project. It provides you a very rough idea of what is the project "ImmUniverse" about.
The following table provides information about the project.
|Coordinator Country||Italy [IT]|
|Total cost||31˙110˙000 €|
|EC max contribution||15˙500˙000 € (50%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2020-01-01 to 2024-12-31|
Take a look of project's partnership.
|1||HUMANITAS UNIVERSITY||IT (PIEVE EMANUELE)||coordinator||1˙970˙093.00|
|2||CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL||DE (KIEL)||participant||2˙613˙900.00|
|3||AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH||AT (WIEN)||participant||2˙133˙236.00|
|4||STICHTING KATHOLIEKE UNIVERSITEIT||NL (NIJMEGEN)||participant||1˙248˙421.00|
|5||JOANNEUM RESEARCH FORSCHUNGSGESELLSCHAFT MBH||AT (GRAZ)||participant||834˙408.00|
|6||KATHOLIEKE UNIVERSITEIT LEUVEN||BE (LEUVEN)||participant||740˙000.00|
|7||UNIVERSITE DU LUXEMBOURG||LU (ESCH-SUR-ALZETTE)||participant||687˙000.00|
|8||THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE||UK (CAMBRIDGE)||participant||659˙793.00|
|9||VIB VZW||BE (ZWIJNAARDE - GENT)||participant||652˙500.00|
|10||EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH||DE (ST INGBERT)||participant||626˙062.00|
|11||ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM||NL (AMSTERDAM)||participant||564˙047.00|
|12||ISTITUTO SUPERIORE DI SANITA||IT (ROMA)||participant||504˙988.00|
|13||LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN||DE (MUENCHEN)||participant||492˙475.00|
|14||INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA||LU (Esch-sur-Alzette)||participant||402˙501.00|
|15||SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO S ANNA||IT (PISA)||participant||362˙000.00|
|16||AARHUS UNIVERSITETSHOSPITAL||DK (AARHUS)||participant||355˙596.00|
|17||CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY||FR (NANCY CEDEX)||participant||340˙783.00|
|18||AARHUS UNIVERSITET||DK (AARHUS C)||participant||199˙847.00|
|19||EUROPEAN FEDERATION OF CROHN'S AND ULCERATIVE COLITIS ASSOCIATIONS||BE (BRUXELLES)||participant||50˙312.00|
|20||EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING||BE (Brussels)||participant||50˙250.00|
|21||FORUM EUROPEEN DES PATIENTS (FPE)||LU (LUXEMBOURG)||participant||11˙781.00|
|22||Eli Lilly and Company Limited||UK (Basingstoke)||participant||0.00|
|23||GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.||UK (BRENTFORD)||participant||0.00|
|24||NOVARTIS PHARMA AG||CH (BASEL)||participant||0.00|
|25||PFIZER LIMITED||UK (SANDWICH)||participant||0.00|
|26||SANOFI-AVENTIS DEUTSCHLAND GMBH||DE (FRANKFURT AM MAIN)||participant||0.00|
Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enormous heterogeneity with regard to disease outcome and response to targeted therapies, which currently cannot be adequately anticipated to tailor individual patient management. Hence, mechanistic understanding of this heterogeneity and biomarkers predictive for disease control and therapy response over time are important prerequisites of a future precision medicine in IMIDs. ImmUniverse has been formed as a European transdisciplinary consortium to tackle these unmet needs and to understand the role of the crosstalk between tissue microenvironment and immune cells in disease progression and response to therapy of two different IMIDs: ulcerative colitis and atopic dermatitis. Following this unique cross-disease approach ImmUniverse will fill the gap and the limitations of current studies, which do not systematically compare the complex interactions between recirculating immune cells and the respective tissue microenvironment. The consortium will combine analysis of tissue-derived signatures with “circulating signatures” detectable in liquid biopsies, employing state-of-the-art profiling technologies corresponding to multi-Omics datasets. The project will also bring diagnostics in IMID to a new level by implementing disruptive non-invasive liquid-biopsy methodology in combination with novel, validated circulating biomarker assays which are expected to improve diagnosis, inform early in the clinical course on disease severity and progression and enable treatment response monitoring. The identified signature will be validated to monitor state/progression and response to therapy in prospective observational cohorts. Realization of these objectives will result in improvement of patient management, lead to increased patient well-being and will significantly reduce the socioeconomic burden of these diseases.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNIVERSE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IMMUNIVERSE" are provided by the European Opendata Portal: CORDIS opendata.
Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.Read More
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
NOVEL GRAM-NEGATIVE ANTIBIOTIC NOWRead More